NASDAQ:YMAB

Y-mAbs Therapeutics News Headlines

$34.20
+5.55 (+19.37 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.78
$34.36
50-Day Range
$25.45
$36.05
52-Week Range
$24.77
$55.22
Volume793,996 shs
Average Volume302,209 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36

Headlines

Y-mAbs Therapeutics (NASDAQ YMAB) News Headlines Today

SourceHeadline
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Buy at Bank of AmericaY-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Buy at Bank of America
marketbeat.com - May 7 at 12:25 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Quarterly  Earnings Results, Beats Expectations By $0.14 EPSY-mAbs Therapeutics (NASDAQ:YMAB) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS
americanbankingnews.com - May 7 at 8:05 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Upgraded to "Buy" at Bank of AmericaY-mAbs Therapeutics (NASDAQ:YMAB) Upgraded to "Buy" at Bank of America
americanbankingnews.com - May 7 at 1:02 PM
Y-mAbs Announces First Quarter Financial Results and Recent Corporate DevelopmentsY-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
finance.yahoo.com - May 6 at 6:52 PM
YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings EstimatesYmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates
finance.yahoo.com - May 6 at 6:52 PM
Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021
finance.yahoo.com - April 29 at 7:33 PM
Y-mAbs Announces Data to be Presented at 2021 ASCO Annual MeetingY-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting
finance.yahoo.com - April 29 at 9:32 AM
Thomas Gad Sells 7,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) StockThomas Gad Sells 7,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock
americanbankingnews.com - April 28 at 4:38 PM
Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines AgencyY-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency
finance.yahoo.com - April 27 at 7:29 PM
When Will Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Breakeven?When Will Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Breakeven?
finance.yahoo.com - April 23 at 1:57 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Sees Unusually-High Trading VolumeY-mAbs Therapeutics (NASDAQ:YMAB) Sees Unusually-High Trading Volume
americanbankingnews.com - April 22 at 1:38 PM
Wedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)Wedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)
americanbankingnews.com - April 21 at 12:44 PM
Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue CancerY-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer
finance.yahoo.com - April 20 at 5:47 PM
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 2.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 2.9%
americanbankingnews.com - April 20 at 1:40 PM
BRIEF-Y-Mabs Therapeutics- Concluded A Type B Meeting With Fdaregarding OmburtamabBRIEF-Y-Mabs Therapeutics- Concluded A Type B Meeting With Fdaregarding Omburtamab
msn.com - April 20 at 12:46 PM
Y-mAbs Provides Regulatory Update on OmburtamabY-mAbs Provides Regulatory Update on Omburtamab
finance.yahoo.com - April 20 at 12:46 PM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $186,270.00 in StockY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $186,270.00 in Stock
americanbankingnews.com - April 14 at 7:52 PM
Y-mAbs Announces GPA33-SADA Data Presented at AACRY-mAbs Announces GPA33-SADA Data Presented at AACR
finance.yahoo.com - April 12 at 12:34 PM
Oversold Conditions For Y-mAbs TherapeuticsOversold Conditions For Y-mAbs Therapeutics
nasdaq.com - March 24 at 7:13 PM
Y-mAbs: Different Data For Different Audiences, Concerning Management History, And Insider Stock Sales - Price Target $16Y-mAbs: Different Data For Different Audiences, Concerning Management History, And Insider Stock Sales - Price Target $16
seekingalpha.com - March 17 at 12:59 PM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Are Reducing Their Forecasts For This YearY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Are Reducing Their Forecasts For This Year
finance.yahoo.com - March 1 at 9:12 AM
Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful?Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - February 25 at 4:37 PM
Y-mAbs Announces 2020 Financial Results and Recent Corporate DevelopmentsY-mAbs Announces 2020 Financial Results and Recent Corporate Developments
finance.yahoo.com - February 25 at 4:37 PM
Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesY-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
markets.businessinsider.com - February 22 at 7:06 PM
Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021
finance.yahoo.com - February 19 at 2:05 PM
Y-mAbs Therapeutics (YMAB) Shares Cross Below 200 DMAY-mAbs Therapeutics (YMAB) Shares Cross Below 200 DMA
nasdaq.com - February 17 at 7:03 PM
United Therapeutics launches first product of 2021 after Covid-related delaysUnited Therapeutics launches first product of 2021 after Covid-related delays
bizjournals.com - February 10 at 5:17 PM
YMAB Feb 2021 70.000 callYMAB Feb 2021 70.000 call
au.finance.yahoo.com - January 17 at 11:22 PM
Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare ConferenceY-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 12:58 PM
Y-mAbs Announces Sale of Priority Review VoucherY-mAbs Announces Sale of Priority Review Voucher
finance.yahoo.com - December 28 at 12:34 PM
Y-mAbs Therapeutics: Further Upside After ApprovalY-mAbs Therapeutics: Further Upside After Approval
seekingalpha.com - December 21 at 11:26 PM
Week In Review: Weeks China Life Science Investments Total $800 MillionWeek In Review: Week's China Life Science Investments Total $800 Million
seekingalpha.com - December 20 at 7:22 PM
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in Eastern EuropeY-mAbs Signs Distribution Agreement with Swixx for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in Eastern Europe
marketwatch.com - December 18 at 3:40 PM
Y-mAbs Signs License Agreement with SciClone for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in ChinaY-mAbs Signs License Agreement with SciClone for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in China
marketwatch.com - December 18 at 3:40 PM
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern EuropeY-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
nasdaq.com - December 18 at 3:40 PM
Y-mAbs Announces Pipeline UpdateY-mAbs Announces Pipeline Update
finance.yahoo.com - December 16 at 9:29 AM
Is YMAB A Good Stock To Buy Now?Is YMAB A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 9:22 PM
Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMOY-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO
finance.yahoo.com - December 9 at 6:06 PM
Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16
finance.yahoo.com - December 7 at 9:17 AM
Insider Sells Y-mAbs Therapeutics StockInsider Sells Y-mAbs Therapeutics Stock
finance.yahoo.com - December 4 at 6:04 PM
FDA Approves Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of NeuroblastomaFDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
benzinga.com - November 25 at 7:08 PM
FDA OKs Y-mAbs neuroblastoma treatmentFDA OKs Y-mAbs' neuroblastoma treatment
seekingalpha.com - November 25 at 7:08 PM
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of NeuroblastomaFDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
finance.yahoo.com - November 25 at 7:08 PM
Y-mAbs Announces Update on Omburtamab in DIPGY-mAbs Announces Update on Omburtamab in DIPG
finance.yahoo.com - November 19 at 10:51 AM
The Daily Biotech Pulse: Lillys COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage StudiesThe Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies
benzinga.com - November 10 at 8:54 AM
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call TranscriptY-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 7:53 AM
Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate DevelopmentsY-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
finance.yahoo.com - November 5 at 8:26 PM
Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020
finance.yahoo.com - October 29 at 9:21 AM
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn RateWe're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
finance.yahoo.com - October 28 at 6:22 PM
Y-mAbs announces FDA clearance for lu-omburtamab-DTPA INDY-mAbs announces FDA clearance for lu-omburtamab-DTPA IND
seekingalpha.com - October 26 at 1:25 PM
Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult IndicationsY-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications
finance.yahoo.com - October 26 at 1:25 PM
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.